WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis
Study results demonstrated significant correlations between fatigue and reductions in walking speed and mobility among patients with multiple sclerosis.
Engaging with healthy lifestyle behaviors, including a healthy diet and physical activity, was associated with better outcomes among patients with multiple sclerosis (MS).
Looking to the future of Alzheimer disease treatment, the panel discusses key takeaways on the evolving therapeutic landscape.
Experts discuss how payers can prepare for new treatments and plan adequate coverage for patients with Alzheimer disease.
Accelerated approval was originally granted in June 2023 for patients aged 4 to 5 years, indicating there was an unmet clinical need for a potentially life-saving treatment for the rare genetic muscle disorder.
An overview of how disease-modifying treatments for Alzheimer disease can impact medical costs and caregiver burden.
The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.
